<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112453">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01679366</url>
  </required_header>
  <id_info>
    <org_study_id>0054-11-ZIV</org_study_id>
    <nct_id>NCT01679366</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients</brief_title>
  <official_title>The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of probiotics to the routine therapy of Acute Pharyngotonsillitis in adult
      patients may shorten the duration, and reduce the severity of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis The addition of probiotics to the routine therapy of AP in adult patients may
      shorten the duration, and reduce the severity of the disease.

      Study design A prospective, randomized, placebo-controlled, double-blinded study comparing
      treatment with probiotics to placebo in patients with  AP.

      The study will be conducted in accordance with the ethical standards of the Helsinki
      Declaration and will be approved by the Human Experimentation Ethics Committee of the Ziv
      Medical Center. Signed informed consent will be required from all patients before inclusion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>period of disease</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be followed daily while hospitalized. After discharge patients will fill a daily dairy for 10 days and record symptoms, signs, drinking, eating, and return to normal life. All dairies will be collected on day 10 of  the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>analysis</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Follow-up throat culture, CBC, CRP, and ESR on day 4 of the study or at discharge if before. For patients with abnormal laboratory tests on admission, repeat tests are performed before discharge according to the routine of the department. For patients with normal tests on admission, these tests will be part of the study. For patients with Streptococcus pyogenes growth on admission and day 4 of the study, another throat culture will be done on day 10 of the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Throat Pain</condition>
  <arm_group>
    <arm_group_label>Penicillin G</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>hospitalization of 30 patients given penicilline intraveniously for 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 hospitalized patients will be given placebo with a regular penicillin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotics will be given to 30 hospitalized patients with regular penicillin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet 2 times daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill for mimic probiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>1 tablet twice daily</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>BLIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Acute pharyngotonsillitis for which hospitalization for intravenous antibiotic
             treatment and/or fluids is needed

        Exclusion Criteria:

          -  Current therapy with systemic prednisone or equivalent at 20 mg/d for more than 10
             days prior to inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonid Livshits, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziv Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonid Livshits, MD</last_name>
    <phone>+972506266061</phone>
    <email>leonid.lv@ziv.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Miron, Proff</last_name>
    <phone>+972508434337</phone>
    <email>miron_da@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonid Livshits, MD</last_name>
      <phone>+972506266061</phone>
      <email>leonid.lv@ziv.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Dan Miron, Proff</last_name>
      <phone>+972508434337</phone>
      <email>miron_da@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>October 23, 2012</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
